September 22, 2005 -- Intarcia Therapeutics, scheduled to make its IPO debut this week, withdrew its application, Sunesis Pharma remains on the docket for this week, the FDA has asked Avanir for more information about Neurodex, which will delay its ruling, Guidant reported problems with two pacemaker models, Myriad Genetics said Flurizan helped Alzheimer’s patients in a 3-month follow-up study, and Janssen will not exercise its option to market Hyphanox, an oral antifungal product from Barrier Therapeutics. The Centient Biotech 200 was off 15 points at 3824, a drop of .39%. More details...
